Suchergebnisse - "Pariente, Benjamin"

PubPharm (153)

51

Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease

enthalten in: Digestive diseases and sciences | 2019

von Hallé, E. | Azahaf, M. | Duveau, N. | +9

52

Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease

enthalten in: Digestive diseases and sciences | 2019

von Hallé, E. | Azahaf, M. | Duveau, N. | +9

53

Radiological Response Is Associated with Better Outcomes and Should Be Considered a Therapeutic Target in Crohn’s Disease

enthalten in: Digestive diseases and sciences | 2019

von Hallé, E. | Azahaf, M. | Duveau, N. | +9

54

T cell clonal expansions in ileal Crohn's disease are associated with smoking behaviour and postoperative recurrence

enthalten in: Gut | 2019

von Allez, M. | Auzolle, C. | Ngollo, M. | +78

55

enthalten in: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | 2019

von Pariente, B. | Louis, E.

CommentOn: Clin Gastroenterol Hepatol. 2019 Apr;17(5):847-856. - PMID 30012430

56

Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease

enthalten in: Joint bone spine | 2019

von Paccou, J. | Nachury, M. | Duchemin, C. | +3

57

Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease

enthalten in: Digestive diseases and sciences | 2019

von Painchart, C. | Brabant, S. | Duveau, N. | +10

58

Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease

enthalten in: Digestive diseases and sciences | 2019

von Painchart, C. | Brabant, S. | Duveau, N. | +10

59

Ustekinumab Serum Trough Levels May Identify Suboptimal Responders to Ustekinumab in Crohn’s Disease

enthalten in: Digestive diseases and sciences | 2019

von Painchart, C. | Brabant, S. | Duveau, N. | +10

60

Vedolizumab Therapy is Ineffective for Primary Sclerosing Cholangitis in Patients With Inflammatory Bowel Disease : A GETAID Multicentre Cohort Study

enthalten in: Journal of Crohn's & colitis | 2019

von Caron, B. | Peyrin-Biroulet, L. | Pariente, B. | +21

CommentIn: J Crohns Colitis. 2019 Sep 27;13(10):1237-1238. - PMID 31560065